bioRxivCancer Biology
Resistance to decitabine and 5-azacytidine emerges from adaptive responses of the pyrimidine metabolism network
X. Gu, R. Tohme, B. Tomlinson, M. Hasipek, L. Durkin, C. Schuerger, A. M. Zidan, T. Radivoyevitch, C. Hong, H. Carraway, B. Hamilton, R. Sobecks, B. K. Jha, E. D. Hsi, J. Maciejewski, Y. Saunthararajah
Abstract
Mechanisms-of-resistance to decitabine and 5-azacytidine, mainstay treatments for myeloid malignancies, require investigation and countermeasures. Both are nucleoside analog pro-drugs processed by pyrimidine metabolism into a nucleotide analog that depletes the key epigenetic regulator DNA methyltranseferase 1 (DNMT1). We report here that DNMT1 protein, although substantially depleted (~50%) in patients bone marrows at response, rebounded at relapse, and explaining this, we found pyrimidine metabolism gene expression shifts averse to the processing of each pro-drug. The same metabolic shifts observed clinically were rapidly recapitulated in leukemia cells exposed to the pro-drugs in vitro. Pyrimidine metabolism is a network that senses and preserves nucleotide balances: Decitabine, a deoxycytidine analog, and 5-azacytidine, a cytidine analog, caused acute and distinct nucleotide imbalances, by off-target inhibition of thymidylate synthase and ribonucleotide reductase respectively. Resulting expression changes in key pyrimidine metabolism enzymes peaked 72-96 hours later. Continuous pro-drug exposure stabilized metabolic shifts generated acutely, preventing DNMT1-depletion and permitting exponential leukemia out-growth as soon as day 40. Although dampening to activity of the pro-drug initially applied, adaptive metabolic responses primed for activity of the other. Hence, in xenotransplant models of chemorefractory AML, alternating decitabine with 5-azacytidine, timed to exploit compensating metabolic shifts, and addition of an inhibitor of a catabolic enzyme induced by decitabine/5-azacytidine, extended DNMT1-depletion and time-to-distress by several months versus either pro-drug alone. In sum, resistance to decitabine and 5-azacytidine emerges from adaptive responses of the pyrimidine metabolism network; these responses can be anticipated and thus exploited. GRAPHICAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=85 SRC="FIGDIR/small/958405v1_ufig1.gif" ALT="Figure 1"> View larger version (35K): org.highwire.dtl.DTLVardef@e3f77aorg.highwire.dtl.DTLVardef@8caaa4org.highwire.dtl.DTLVardef@117236dorg.highwire.dtl.DTLVardef@16ee98_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- assay: bulk RNA-seq
- research focus: cancer & tumor microenvironment
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The type of DNA damage response after Decitabine treatment depends on the level of DNMT activity
T. Aumer, L. Bergmayr, … F. R. Traube·bioRxiv·Sep 2, 2023
- The CD112-TIGIT/PVRIG Axis Mediates NK Cell Evasion inDecitabine-Treated Acute Myeloid Leukemia Cells
Keisuke Nakamura, Ikuko Omori, … Yutaka Enomoto·bioRxiv·Sep 10, 2026
- Macrophage-secreted Pyrimidine Metabolites Confer Chemotherapy Resistance in Acute Myeloid Leukemia (AML)
Chuqi Wang, Yuhan Wang, … Shruti Bhatt·bioRxiv·Nov 1, 2025
- Epigenetic anti-cancer treatment with a stabilized carbocyclic Decitabine analogue
F. R. Traube, N. F. Bras, … T. Carell·bioRxiv·Jan 19, 2022
- Cell-state-specific mechanisms of 5-azacytidine response in myelodysplastic neoplasms
Golam Sarower Bhuyan, Feng Yan, … John E. Pimanda·bioRxiv·Jul 20, 2026
- Pan-cancer analysis of pyrimidine metabolism reveals signaling pathways connections with chemoresistance role
V. Ramesh, M. Demirdizen, … P. Ceppi·bioRxiv·Dec 6, 2023